ABSTRACT
Introduction
Oral squamous cell carcinoma (OSCC) is the most frequent malignant tumor of the oral cavity around the world. [1] Conclusive local therapies defined as surgery, radiation therapy, or both are the conventional treatment approaches in OSCC. However, OSCC is associated with high rates of local and distant recurrences. Treatments can cause considerable morbidity, including loss of swallowing ability, and also tongue and larynx dysfunction. Improved cure rates and functional outcomes have led to adding chemotherapy to the treatment of OSCC. Combined modality of the treatment has advantages such as functional organ preservation in patients with locoregionally advanced head and neck cancer. [2] Neoadjuvant chemotherapy in OSCC has been investigated. Despite the absence of absolute scientific evidence; it is often used in clinical practice based on biological and practical considerations. [3] It has been shown that untreated OSCC is chemosensitive; besides, multiple agent chemotherapy has a response rate in approximately 70-80% of tumors. [3] Some studies showed that induction chemotherapy decreased distant metastasis (DM) without improvement of survival rates. [3] Other studies demonstrated a benefit of neoadjuvant chemotherapy in OSCC. [4] [5] The effect of neoadjuvant chemotherapy on local recurrence (LR) rate is still controversial. Few studies focused on outcomes of neoadjuvant chemotherapy in treatment of OSCC in various tumor sizes and lymph node involvements. [6] The aim of this study was to evaluate the effect of neoadjuvant chemotherapy on decrease of LR and DM in OSCC.
Materials and Method
The samples in this retrospective cohort study were de- The LR and DM were documented in each patient and have been proven by histopathological evaluation.
Tumor size and lymph node have been documented according to the tumor staging system for SCC (Table   1 ). [7] Tumor size, lymph node involvement, age and follow-up time were considered as variable factors of the study. The LR and DM were outcomes of the study. Licitra et al. [19] demonstrated that adding primary chemotherapy to standard surgery did not improve survival. However, in his study, primary chemotherapy seemed to play a role in reducing the number of patients who needed to undergo mandibulectomy and/or radiation therapy. Variations in the criteria used to select the patients for these treatment options make it difficult to generalize these results. But, it appeared that using preoperative chemotherapy to spare destructive surgery or radiation therapy in patients with advanced, resectable oral cavity cancer was reasonable. It is well known that primary surgery with adjuvant radiation or chemoradiation was complementary to primary chemoradiotherapy for nonresectable tumors. Ongoing studies are sorting out the role of induction chemotherapy in the current context of clarifying optimal multimodal treatment. [20] In one study, [21] patients (21%) died due to tumor recurrence, and 33 (15%) deaths were not directly related to the primary tumor. Overall, the survival probability was 76% after two years and 62% after five years. Two-and five-year local control probabilities were 88 and 81%, respectively. The authors concluded that the multimodal concept was an effective therapy offering excellent survival and local control probability. [22] Recently, it is claimed that current data would not Two agents were used in our study for chemotherapy. It was a main limitation of this study. Use of a combination of other chemotherapy agents may change the outcome of the study. Moreover, increasing the number of cases enhances the reliability of the study.
Results

Ninety
Further clinical trials are necessary to evaluate various chemotherapy protocols in treatment of OSCC patients.
Conclusion
Based on our results, neoadjuvant chemotherapy with combination of cisplatin and 5-fluorouracil may not improve the prognosis of OSCC. However, further studies are suggested to assess other neoadjuvant chemotherapy protocols in OSCC patients.
